SA
FMCQF

S&P 500, Nasdaq, Russell 2000 below the 200-day average · VIX 35.9 · very high volatility

Overview →

Fresenius Medical Care AG & Co. KGaA (FMCQF)

R&D to Revenue

0.80%

Fiscal year · Period ending:

FMCQF logo

FMCQF R&D to Revenue

Latest reported0.80%
FMCQF FY R&D/Revenue (0.00% → 0.80%)
High-resolution chart · PNG

What is r&d to revenue?

R&D spending as percentage of revenue.

FMCQF r&d to revenue history

Annual fiscal periods. Dates are reporting period ends; fiscal years can differ from calendar years. Change compares each value with the period before it, in percentage points.

Fresenius Medical Care AG & Co. KGaA R&D to Revenue — Annual fiscal periods
Period endingR&D to RevenueChange
0.805%−0.14 pts
0.949%−0.24 pts
1.1924%+0.01 pts
1.1786%−0.08 pts
1.2543%+0.17 pts
1.0863%+0.13 pts
0.9613%+0.15 pts
0.8098%+0.07 pts
0.7366%−0.17 pts
0.9045%+0.07 pts
0.8364%+0.07 pts
0.7706%−0.09 pts
0.8611%+0.05 pts
0.8089%−0.06 pts
0.8662%+0.07 pts
0.8009%−0.03 pts
0.8341%+0.08 pts
0.7561%+0.07 pts
0.6844%+0.08 pts
0.6035%−0.15 pts
0.7525%−0.07 pts
0.8247%−0.07 pts
0.8989%−0.03 pts
0.933%+0.20 pts
0.7347%−0.03 pts
0.7601%−0.09 pts
0.8459%−0.04 pts
0.89%+0.89 pts
0%—

Frequently asked questions: FMCQF r&d to revenue

What is Fresenius Medical Care AG & Co. KGaA (FMCQF)'s current r&d to revenue?

Fresenius Medical Care AG & Co. KGaA (FMCQF)'s latest reported r&d to revenue (Fiscal year) is 0.80% as of Dec 31, 2025. R&D spending as percentage of revenue.

How much historical r&d to revenue data is available for FMCQF?

Stock Alarm Pro provides 29 dated annual fiscal periods observations for Fresenius Medical Care AG & Co. KGaA (FMCQF)'s r&d to revenue, allowing investors to analyze multi-year trends and cycle inflection points in Chart Studio.

How can I compare FMCQF's r&d to revenue to peers or set an alert?

You can open FMCQF's r&d to revenue in Stock Alarm Pro Chart Studio to overlay price and valuation multiples, or set real-time alerts on FMCQF delivered by push, email, or phone call.

Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.